Here are the DEF 14A proxy statements from Pharm-Bio Serv Inc (PBSV) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PBSV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBSV filings page.
Pharma-Bio Serv, Inc. is holding its 2026 Annual Meeting on May 15, 2026 in Boca Raton, Florida to elect one Class I director and ratify its independent auditor. Stockholders of record at the close of business on April 8, 2026, when 22,901,692 shares of common stock were outstanding, may vote.
The Board proposes re-electing long‑time director Irving Wiesen to a term running through the 2029 meeting and ratifying Crowe PR PSC as auditor for the year ending October 31, 2026. All four directors are deemed independent under Nasdaq standards, and committee structures for audit, compensation, nominating/governance, and M&A are described.
The proxy details 2025 director retainers of $50,000 plus annual option grants of 20,000 shares, and executive salaries including $231,000 for CEO Victor Sanchez and $175,000 for CFO Pedro Lasanta. Audit, audit‑related and other fees to Crowe totaled $113,740 in fiscal 2025. Procedures for attending, registering, submitting proposals, and nominating directors in future years are also outlined.